Soo Ryum Yang, MD
Pathology · New York
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 12 years
- Graduated 2014
Offices
1 location · Memorial Pathology Group · 98 clinicians in this group
Hospitals listed: Memorial Hospital for Cancer and Allied Diseases · NYU Langone Hospitals. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Yang’s office at (212) 639-2000 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- NYU Langone HospitalsNew York, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of NYU Langone Health, which runs 5 hospitalsHome of Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 11.9 (10.8 to 13.2) · 2,678 cases, Jan 2024 – Dec 2024Better than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.67 (0.56 to 0.78), Jul 2022 – Jun 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 110.18 (84.1 to 136.26) · 561 cases, Jul 2022 – Jun 2024Better than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 2.66 (1.81 to 3.51) · 16,112 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 3.24 (1.36 to 5.12) · 9,218 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 2.56 (1.28 to 3.83) · 9,540 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.39, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.097, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.529, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.7 (3.1 to 4.4) · 2,678 cases, Jan 2024 – Dec 2024Better than the national rate — Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies): 10.5 (9.1 to 12.3) · 10,521 cases, Jan 2022 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.7 to 0.8) · 6,063 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for NYU Langone Hospitals
Behind the star rating — Deaths: 8 better, 0 the same, 0 worse of 8 measures. Safety: 5 better, 2 the same, 1 worse of 8 measures. Readmissions: 8 better, 1 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.9 (10.8 to 13.2) · 2,678 cases | Worse | Jan 2024 – Dec 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.67 (0.56 to 0.78) | Better | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 110.18 (84.1 to 136.26) · 561 cases | Better | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.66 (1.81 to 3.51) · 16,112 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 3.24 (1.36 to 5.12) · 9,218 cases | Better | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 2.56 (1.28 to 3.83) · 9,540 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.097 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.529 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 3.7 (3.1 to 4.4) · 2,678 cases | Better | Jan 2024 – Dec 2024 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.5 (9.1 to 12.3) · 10,521 cases | Better | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.7 to 0.8) · 6,063 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.48 (0.95 to 2.01) · 9,995 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 331 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 5.2 · 532 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 6.7 · 547 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 5.2 · 2,910 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 8 · 4,115 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 7.4 · 1,351 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 1.6 · 23,286 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0.01 to 0.24) · 48,461 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.12 to 0.34) · 50,693 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0.66 to 2.11) · 9,390 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.79 (0.99 to 2.59) · 12,979 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.62 (0.53 to 2.72) · 3,510 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.38 to 0.82) · 40,829 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.8 · 3,298 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.091 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.859 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.3 · 667 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 18.7 · 4,060 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -23.8 · 603 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.8 · 3,334 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.5 · 4,338 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 5,069 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 3.7 · 3,383 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 6.8 · 386 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 820 cases | None | Jul 2023 – Jun 2025 |
What patients said (10,034 patients answered, 23% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$62,571
Medicare paid this office $62,571 for 782 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Molecular pathology procedure; physician interpretation and report | 635 | $29,735 | $39 |
| Special stained specimen slides to examine tissue, each additional procedure | 40 | $3,776 | $23 |
| Pathology examination of tissue using a microscope, intermediate complexity | 60 | $3,701 | $31 |
| Pathology examination of tissue using a microscope, moderately high complexity | 28 | $3,538 | $68 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 45 | $3,190 | $71 |
See all 11 services
| Molecular pathology procedure; physician interpretation and report | 635 | $29,735 | $39 |
| Special stained specimen slides to examine tissue, each additional procedure | 40 | $3,776 | $23 |
| Pathology examination of tissue using a microscope, intermediate complexity | 60 | $3,701 | $31 |
| Pathology examination of tissue using a microscope, moderately high complexity | 28 | $3,538 | $68 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 45 | $3,190 | $71 |
| Microscopic genetic analysis of tumor, manual | 40 | $2,054 | $34 |
| Special stained specimen slides to examine tissue, initial procedure | 53 | $1,646 | $29 |
| Pathology examination of tissue using a microscope, high complexity | 12 | $1,391 | $116 |
| Microscopic genetic analysis of tissue, manual, initial procedure | 31 | $1,081 | $35 |
| Pathology examination of specimen during surgery, first tissue block | 13 | $1,080 | $51 |
| Special stained specimen slides to identify organisms including interpretation and report | 15 | $795 | $22 |
Who their Medicare patients are
782 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 7% · Women 57% · Also on Medicaid 10% · Health risk score 2.28. Above the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 75% · Cancer 71% · Coronary heart disease 36% · COPD 29% · Diabetes 28% · Depression 24% · Chronic kidney disease 20% · Atrial fibrillation 17% · Heart failure 13% · Stroke 12% · Dementia 7%.
The office billed $329,890, Medicare allowed $76,496 and paid $62,571; for 1,392 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 782 | 1,392 | 74 | 2.28 | $329,890 | $62,571 |
| 2023 | 792 | 1,664 | 74 | 1.97 | $381,635 | $70,992 |
| 2022 | 834 | 1,346 | 73 | 2.10 | $287,737 | $57,047 |
| 2021 | 379 | 584 | 74 | 1.75 | $113,110 | $23,443 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Molecular pathology procedure; physician interpretation and report | 623 | $30,605 | $41 |
| Special stained specimen slides to examine tissue, each additional procedure | 68 | $6,614 | $24 |
| Pathology examination of tissue using a microscope, high complexity | 27 | $5,565 | $124 |
| Pathology examination of tissue using a microscope, intermediate complexity | 74 | $5,420 | $32 |
| Pathology examination of tissue using a microscope, moderately high complexity | 26 | $4,312 | $71 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 47 | $3,511 | $73 |
| Microscopic genetic analysis of tumor, manual | 66 | $2,908 | $35 |
| Special stained specimen slides to examine tissue, initial procedure | 72 | $2,431 | $30 |
| Microscopic genetic analysis of tissue, manual, initial procedure | 37 | $1,344 | $35 |
| Pathology examination of specimen during surgery, first tissue block | 13 | $1,327 | $53 |
| Special stained specimen slides to identify organisms including interpretation and report | 13 | $634 | $23 |
| Special stained specimen slides to examine tissue including interpretation and report | 12 | $135 | $10 |
2022: 8 services
| Molecular pathology procedure; physician interpretation and report | 710 | $35,915 | $41 |
| Special stained specimen slides to examine tissue, each additional procedure | 41 | $3,395 | $25 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 39 | $2,938 | $75 |
| Pathology examination of tissue using a microscope, intermediate complexity | 50 | $2,194 | $33 |
| Pathology examination of tissue using a microscope, moderately high complexity | 11 | $1,900 | $73 |
| Special stained specimen slides to examine tissue, initial procedure | 47 | $1,514 | $30 |
| Microscopic genetic analysis of tumor, manual | 30 | $1,305 | $36 |
| Microscopic genetic analysis of tissue, manual, initial procedure | 30 | $1,110 | $36 |
2021: 6 services
| Molecular pathology procedure; physician interpretation and report | 347 | $17,752 | $42 |
| Special stained specimen slides to examine tissue, each additional procedure | 15 | $1,579 | $25 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 12 | $924 | $77 |
| Pathology examination of tissue using a microscope, intermediate complexity | 15 | $702 | $33 |
| Microscopic genetic analysis of tumor, manual | 15 | $673 | $37 |
| Special stained specimen slides to examine tissue, initial procedure | 17 | $532 | $31 |
Medicaid work
$684 in 2024
Medicaid paid $684 for 33 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Molecular pathology procedure; physician interpretation and report | 33 | $684 |
| 2024 | 33 | 1 | 17 | $684 |
| 2023 | 48 | 1 | 18 | $1,425 |
| 2022 | 46 | 1 | 14 | $771 |
See the largest Medicaid services in earlier years
2023
| Molecular pathology procedure; physician interpretation and report | 48 | $1,425 |
2022
| Molecular pathology procedure; physician interpretation and report | 46 | $771 |
Money from drug and device companies
$26,074 in 2025
| 2025 | 5 | 35 | $19,914 | $26,074 |
| 2024 | 4 | 12 | $13,944 | $15,365 |
| 2023 | 2 | 18 | $15,970 | $18,136 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Emrelis | $12,206 | 16 payments
|
| Eli Lilly and | None | $5,250 | 2 payments
|
| Roche Molecular Systems | None | $4,529 | 10 payments
|
| Roche Diagnostics | Ventana Pdl1 Sp142 Assay | $3,860 | 6 payments
|
| Leica Microsystems | None | $229 | 1 payment
|
See all 35 published payments
| Abbvie | Consulting · 2025-12-30 | None | $700 |
| Eli Lilly and | Paid to speak or teach · 2025-11-13 | None | $4,200 |
| Eli Lilly and | Paid to speak or teach · 2025-11-13 | None | $1,050 |
| Roche Diagnostics | Paid to speak or teach · 2025-10-28 | None | $2,528 |
| Roche Diagnostics | Paid to speak or teach · 2025-10-21 | None | $532 |
| Abbvie | Travel · 2025-09-24 | Emrelis | $46 |
| Abbvie | Meals · 2025-09-24 | Emrelis | $76 |
| Abbvie | Consulting · 2025-09-24 | Emrelis | $3,675 |
| Roche Diagnostics | Travel · 2025-09-14 | Ventana Pdl1 Sp142 Assay | $297 |
| Abbvie | Meals · 2025-09-12 | Emrelis | $25 |
| Abbvie | Meals · 2025-09-12 | Emrelis | $70 |
| Abbvie | Meals · 2025-09-12 | Emrelis | $25 |
| Abbvie | Travel · 2025-09-11 | Emrelis | $162 |
| Roche Diagnostics | Travel · 2025-08-26 | Ventana Pdl1 Sp142 Assay | $258 |
| Roche Diagnostics | Travel · 2025-08-26 | Ventana Pdl1 Sp142 Assay | $20 |
| Roche Diagnostics | Travel · 2025-08-21 | None | $225 |
| Abbvie | Consulting · 2025-08-13 | None | $2,100 |
| Leica Microsystems | Paid to speak or teach · 2025-07-04 | None | $229 |
| Roche Molecular Systems | Meals · 2025-06-10 | None | $46 |
| Roche Molecular Systems | Travel · 2025-06-10 | None | $89 |
| Roche Molecular Systems | Paid to speak or teach · 2025-06-10 | None | $1,500 |
| Abbvie | Consulting · 2025-05-20 | None | $2,800 |
| Abbvie | Travel · 2025-05-07 | None | $794 |
| Abbvie | Travel · 2025-05-07 | None | $446 |
| Abbvie | Travel · 2025-05-07 | None | $307 |
| Abbvie | Meals · 2025-05-06 | None | $73 |
| Abbvie | Travel · 2025-05-05 | None | $307 |
| Roche Molecular Systems | Travel · 2025-04-03 | None | $47 |
| Roche Molecular Systems | Travel · 2025-04-02 | None | $279 |
| Roche Molecular Systems | Education · 2025-04-01 | None | $850 |
| Roche Molecular Systems | Travel · 2025-04-01 | None | $279 |
| Roche Molecular Systems | Travel · 2025-04-01 | None | $42 |
| Roche Molecular Systems | Travel · 2025-04-01 | None | $1,118 |
| Roche Molecular Systems | Travel · 2025-03-31 | None | $279 |
| Abbvie | Consulting · 2025-02-27 | Emrelis | $600 |
See earlier years (2024, 2023)
2024: $15,365
| Roche Diagnostics | None | $7,956 | 6 payments
|
| Abbvie | None | $2,850 | 4 payments
|
| Amgen | None | $2,744 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $1,815 | 1 payment
|
2023: $18,136
| AstraZeneca UK | None | $16,081 | 15 payments
|
| Genzyme | None | $2,055 | 2 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1669892105
- Licence
- NY 297170
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Student in a training program (390200000X)
- Mailing address
- 1275 York Ave Dept of, New York, NY, 10065
- NPI first listed
- 2014-04-23
- NPI last updated
- 2021-07-20
- NPI record certified
- 2021-07-20
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr Rm L235, Stanford, CA, 94305